Outcome of Board meeting held on Friday, May 23, 2025 at 11.30 AM for approval of Financial results as on March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Minute windows have no benchmark: there is no intraday index history to compare against.
Clinitech Laboratory's Board approved audited financial results for FY ended March 31, 2025, with the auditor issuing an unmodified (clean) opinion. Total income rose to ₹846.26 lakhs from ₹643.92 lakhs in the previous year, a growth of about 31%. Revenue from operations grew nearly 29% to ₹823.49 lakhs. Profit after tax increased modestly to ₹39.47 lakhs (vs ₹37.12 lakhs), while EPS dipped to ₹1.90 from ₹2.37 due to share issuance from the IPO. Operating cash flow remained negative at ₹(87.87) lakhs, though improved from ₹(128.14) lakhs last year. The company has utilised about ₹378.30 lakhs of its ₹578.30 lakhs IPO proceeds, with ₹200 lakhs still unutilised for the expansion of its diagnostic business.
Strong top-line growth driven by revenue expansion is positive, but flat PAT and negative operating cash flow indicate margin pressure and working capital strain. For shareholders, the unutilised IPO funds earmarked for diagnostic business expansion will be a key milestone to watch, as execution on this could drive future earnings.